Received May 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
Patient's mother did not report any symptoms or side effects for the patient./No additional AE; Patient's mother reporting an AE for GARDASIL 9 on behalf of the patient. Patient's mother reported that the patient, who is 20 years old, received his first dose of GARDASIL 9 in "August 2024", but the patient never received his second dose. Patie; This spontaneous report was received from the patient's mother and refers to a 20-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. In August 2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Injection (0.5 ml, strength, route, lot number and expiration date were unknown) for prophylaxis. The Patient's mother reported that the patient never received his second dose in 2025 (inappropriate schedule of product administration). The patient's mother did not report any symptoms or side effects for the patient/No additional adverse event (No adverse event). Due to the patient's mother declining to provide further information, no patient information was collected, and no healthcare professional information was collected.